Advertisement

Topics

Skin And Soft Tissue Infections - Pipeline Review, H1 2015

07:44 EDT 11 Aug 2015 | BioPortfolio Reports

Recently added to the BioPortfolio report store, Skin And Soft Tissue Infections - Pipeline Review, H1 2015 is a new report from Global Markets Direct published on 2015-06-29. This 137-page report is available in PDF from $2000.

Skin And Soft Tissue Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Skin And Soft Tissue Infections - Pipeline Review, H1 2015’, provides an overview of the Skin And Soft Tissue Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Skin And Soft Tissue Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Skin And Soft Tissue Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Skin And Soft Tissue Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Skin And Soft Tissue Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Skin And Soft Tissue Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Skin And Soft Tissue Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Skin And Soft Tissue Infections Overview 10
Therapeutics Development 11
Pipeline Products for Skin And Soft Tissue Infections - Overview 11
Pipeline Products for Skin And Soft Tissue Infections - Comparative Analysis 12
Skin And Soft Tissue Infections - Therapeutics under Development by Companies 13
Skin And Soft Tissue Infections - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Skin And Soft Tissue Infections - Products under Development by Companies 20
Skin And Soft Tissue Infections - Companies Involved in Therapeutics Development 22
Allergan Plc 22
Atox Bio Inc. 23
Cempra, Inc. 24
CorMedix, Inc. 25
CrystalGenomics, Inc. 26
Debiopharm International S.A. 27
Dong-A Socio Group 28
GlaxoSmithKline Plc 29
Melinta Therapeutics, Inc 30
MicuRx Pharmaceuticals, Inc. 31
Motif Bio Plc 32
Nabriva Therapeutics AG 33
NovaDigm Therapeutics, Inc. 34
Phosphagenics Limited 35
Takeda Pharmaceutical Company Limited 36
Tetraphase Pharmaceuticals Inc. 37
The Medicines Company 38
Wockhardt Limited 39
Skin And Soft Tissue Infections - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
AB-103 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
acorafloxacin hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BC-7013 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ceftaroline fosamil - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
CG-400549 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
CRMD-004 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Debio-1450 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Debio-1452 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
delafloxacin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
eravacycline - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
fusidic acid - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
gepotidacin mesylate - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
iclaprim mesylate …

For more information open Skin And Soft Tissue Infections - Pipeline Review, H1 2015.

SKU: GMDHC6488IDB

Original Article: Skin And Soft Tissue Infections - Pipeline Review, H1 2015

NEXT ARTICLE

More From BioPortfolio on "Skin And Soft Tissue Infections - Pipeline Review, H1 2015"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...